Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Possis Medical AngioJet XMI-RX

This article was originally published in The Gray Sheet

Executive Summary

Rapid-exchange version of the firm's XMI Rheolytic thrombectomy catheter is approved via PMA supplement for coronary use with the firm's AngioJet system. Previously approved for peripheral use, XMI-RX also has received a CE mark for coronary use in Europe, clearing the way for its launch at the Paris Course on Revascularization meeting May 25-28. The firm expects the catheter to boost AngioJet market penetration (1"The Gray Sheet" Feb. 23, 2004, p. 21)...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT020291

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel